83 results on '"Kimby, Eva"'
Search Results
2. Treatment Sequencing and Survival in Follicular Lymphoma: A National Population-Based Study
3. Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III/IV
4. Distinct clinical and genetic features of hepatitis B virus–associated follicular lymphoma in Chinese patients
5. Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials
6. Diversity of Intratumoral Regulatory T Cells in Non-Hodgkin Lymphoma
7. Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials
8. Outcome By Primary Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A Large, Population-Based Study in Sweden
9. Bortezomib in Combination with Dexamethasone, Rituximab and Cyclophosphamide (B-DRC) As First - Line Treatment of Waldenstrom's Macroglobulinemia: Results of a Prospectively Randomized Multicenter European Phase II Trial
10. Heterogeneity of Regulatory T Cells in B-Cell Non-Hodgkin Lymphoma
11. A Multistate Survival Analysis for Patients with Follicular Lymphoma (FL) Using 13 First-Line Randomized Trials from FL Analysis of Surrogate Hypothesis (FLASH) Group
12. Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy
13. The PRIMA-Prognostic Index (PI) Is Valid in Follicular Lymphoma (FL) Patients with Rituximab Chemo-Free First-Line Treatment
14. Continuous Increasing Prevalence of Chronic Lymphocytic Leukemia (CLL) with an Estimated Future Rise—a Nationwide Population-Based Study from Sweden
15. M7-FLIPI Not Valid in Follicular Lymphoma Patients with First-Line Rituximab Chemo-Free Therapy
16. High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies
17. Very Early Effects of Ibrutinib on Tumor and Immune Cells in Blood and Lymph Nodes in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Patients
18. Rituximab Plus Lenalidomide Versus Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. First Analysis of Survival Endpoints of the Randomized Phase-2 Trial SAKK 35/10
19. Immune Cell Dynamics in Nordic FL Patients in the SAKK 35/10 Randomized Trial with Rituximab and Lenalidomide
20. Outcomes for Elderly Patients (pts) with Follicular Lymphoma (FL) Using Individual Patient Data (IPD) from 5922 Pts in 18 Randomized Controlled Trials (RCTs): a Follicular Lymphoma Analysis of Surrogate Hypothesis (FLASH) Group Study
21. Waldenstrom's Macroglobulinemia and Overall Survival in Relation to Prognostic Factors and First Line Treatment: An Observational Study from Swedish Lymphoma Registry
22. Treatment recommendations from the Eighth International Workshop on Waldenström’s Macroglobulinemia
23. Sequential Immune Cell Modulation in Nordic Follicular Lymphoma Patients in the SAKK 35/10 Randomized Trial with Rituximab and Lenalidomide
24. Primary Results of the Health-Related Quality of Life Assessment from the Phase III Gadolin Study of Obinutuzumab Plus Bendamustine Compared with Bendamustine Alone in Patients with Rituximab-Refractory, Indolent Non-Hodgkin Lymphoma
25. Rituximab Purging and Maintenance Improves Progression Free Survival but Not Overall Survival In Patients with Relapsed or Resistant Follicular Lymphoma Prior Receiving An Autologous Transplant
26. Serum cytokines in follicular lymphoma
27. Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?
28. Rituximab Plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. Primary Endpoint Analysis of the Randomized Phase-2 Trial SAKK 35/10
29. Follicular Lymphoma Survival in Sweden in the Rituximab Era
30. Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus
31. Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL
32. Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma
33. A Multicenter, Phase IV Observational Study Of Ofatumumab In Chronic Lymphocytic Leukemia (CLL): A European Research Initiative On CLL (ERIC) Study
34. T-Cell Frequencies In MCL Are Of Prognostic Importance In a Large Population-Based Cohort
35. Prognostic Assessment In Patients With Chronic Lymphocytic Leukemia (CLL) In Clinical Practice: A European Research Initiative On CLL (ERIC) Survey
36. Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911)
37. Safety and Immunogenicity Of Inactivated Varicella-Zoster Virus Vaccine In Adults With Hematologic Malignancies Receiving Treatment With Anti-CD20 Monoclonal Antibodies
38. The EBMT Lymphoma Working Party-European Mantle Cell Lymphoma Network Consensus Project On The Role Of Autologous and Allogeneic Stem Cell Transplantation In Mantle Cell Lymphoma: Recommendations Applying The Delphi Procedure
39. SOX11 Directly Represses Wnt/β-Catenin Signaling and Identifies a Subgroup of Mantle Cell Lymphoma Patients with Improved Survival with Intensive Treatment
40. Rituximab (R) in Combination with Interferon-a2a (IFN) Versus Single R in Patients with Follicular or Other CD20+ Low-Grade (indolent) Lymphoma. Final Results From a Randomized Phase III Study From the Nordic Lymphoma Group
41. Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma
42. Immunochemotherapy with Low-Dose Subcutaneous Alemtuzumab (A) Plus Oral Fludarabine and Cyclophosphamide (FC) Is Safe and Induces More and Deeper Complete Remissions in Untreated Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) Than Chemotherapy with FC Alone. An Early Analysis of the Randomized Phase-III HOVON68 CLL Trial
43. Prognostic Impact of Clinical and Tumor Associated Variables in a Population-Based Cohort of Mantle Cell Lymphomas in the Stockholm Region Between 1998–2010
44. SOX11 Expression Versus Indolent Clinical Course in Mantle Cell Lymphomas in a Population-Based Cohort From the Stockholm Region – SOX11 Negative Tumors Are Mostly p53 Positive, Contributing to Shorter Overall Survival,
45. Increasing Grades of Follicular Lymphoma Correlate with Better Prognosis in Patients Treated with Rituximab
46. Rituximab Purging and Maintenance Improves Progression Free Survival but Not Overall Survival In Patients with Relapsed or Resistant Follicular Lymphoma Prior Receiving An Autologous Transplant
47. Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study)
48. Cytogenetic Abnormalities In the Spleen In CLL Patients.
49. Several Immune Cell Subsets Are Associated with Outcome in the Microenvironment of Follicular Lymphoma.
50. Response Is Seen to Conjugate Vaccine but Not to Polysaccharide Vaccine Twelve Months After Rituximab.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.